A new investment partnership between West Pharmaceutical Services and NanoPass Technologies will provide West with access to NanoPass’ knowledge in intradermal drug delivery
West's investment will also allow NanoPass to advance its clinical development efforts and support the launch of its microneedle-based device for intradermal delivery of vaccines and drugs, according to West.
Eric Resnick, vice president and chief technology officer, innovation and technology, West, said: "We expect that advances in intradermal drug delivery will be critical to realising the full potential of some of the pharmaceutical and biotechnology industry's latest advancements in immunotherapy treatments.
"The microneedle technology developed by NanoPass complements our growing portfolio of drug delivery solutions at West, including our own Intradermal Adapter.
“We believe NanoPass has made great strides in this specialised area of drug delivery and we look forward to our partnership."
Yotam Levin, chief executive, NanoPass, said: "We are delighted to enter into this strategic partnership with West, a recognised global leader in the integrated containment and delivery of injectable drugs.
"We share a vision of enabling new vaccines, cancer and allergy immunotherapies with our intradermal injection technology and envision significant synergies in production, marketing and future device developments.
“We could not have found a more suitable partner with the global reach, capacity and related expertise to grow NanoPass to the next level."